Lund, Sweden, 23 October 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that Dr. Magnus Hansson will be appointed as Chief Medical Officer, effective as of 1 ...

CicloMulsion® development to continue in acute kidney injury and increased focus on development of other drug candidates. Shareholder information meeting to be held on 10th September 2015 in Lund, Swe ...

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, reports that the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart attack known as ST-segment el ...

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that NeuroVive Pharmaceutical Asia group has signed a collaboration agreement with Sanofi's local affiliate for the de ...

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that one of its insider registered persons has executed a limited share sale following completed share swaps from Maas ...

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, expects to announce the topline result of the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart ...

The results of a clinical phase II study indicating that cyclosporine counteracts brain injury in a subset of stroke patients undergoing thrombolysis has been published in an article co-authored by on ...

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the first patient has been enrolled in a clinical phase II study for acute kidney injury using the company's prod ...

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the independent safety committee has endorsed moving on to the next dose level without any safety issues, followi ...

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has established a subsidiary in Lyon, France. The establishment is part of a process of extending its ongoing collaboration with ...

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's development project NVP014 for the treatment of ischemic stroke is entering a new phase in coll ...